 C-Peptide
"C-Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
| Descriptor ID |
D002096
|
| MeSH Number(s) |
D06.472.699.587.200.500.250 D12.644.548.586.200.500.250
|
| Concept/Terms |
C-Peptide- C-Peptide
- C Peptide
- Connecting Peptide
- Proinsulin C-Peptide
- Proinsulin C Peptide
- C-Peptide, Proinsulin
- C Peptide, Proinsulin
|
Below are MeSH descriptors whose meaning is more general than "C-Peptide".
Below are MeSH descriptors whose meaning is more specific than "C-Peptide".
This graph shows the total number of publications written about "C-Peptide" by people in this website by year, and whether "C-Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 0 | 3 | 3 | | 2010 | 2 | 4 | 6 | | 2011 | 0 | 2 | 2 | | 2012 | 3 | 2 | 5 | | 2013 | 4 | 5 | 9 | | 2014 | 2 | 3 | 5 | | 2015 | 1 | 4 | 5 | | 2016 | 1 | 7 | 8 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 6 | 9 | | 2019 | 0 | 3 | 3 | | 2020 | 2 | 2 | 4 | | 2021 | 2 | 7 | 9 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 7 | 7 | | 2024 | 2 | 3 | 5 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "C-Peptide" by people in Profiles.
-
Hohenstein AC, Gallegos JB, Dang M, Groegler J, Broncucia H, Tensun FA, Waugh K, Dong F, James EA, Speake C, Steck AK, Rewers MJ, Gottlieb PA, Haskins K, Delong T, Baker RL. Novel T-Cell Reactivities to Hybrid Insulin Peptides in Islet Autoantibody-Positive At-Risk Individuals. Diabetes. 2025 Jun 01; 74(6):933-942.
-
Triolo TM, Parikh HM, Tosur M, Ferrat LA, You L, Gottlieb PA, Oram RA, Onengut-Gumuscu S, Krischer JP, Rich SS, Steck AK, Redondo MJ. Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):e1046-e1050.
-
Roshandel D, Spiliopoulou A, McGurnaghan SJ, Iakovliev A, Lipschutz D, Hayward C, Bull SB, Klein BEK, Lee KE, Kinney GL, Rewers M, Costacou T, Miller RG, McKeigue PM, Paterson AD, Colhoun HM. Genetics of C-Peptide and Age at Diagnosis in Type 1 Diabetes. Diabetes. 2025 Feb 01; 74(2):223-233.
-
Jones AG, Shields BM, Oram RA, Dabelea DM, Hagopian WA, Sharp SA, Lustigova E, Shah AS, Knupp J, Mottl AK, D'Agostino RB, Williams A, Marcovina SM, Pihoker C, Divers J, Redondo MJ. Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2024 Dec 01; 47(12):2110-2119.
-
Triolo TM, Jacobsen LM, Cuthbertson D, Sims EK, Ismail HM, Redondo MJ, Lundgren M, DiMeglio LA, Gottlieb PA, Atkinson MA, Krischer JP, Schatz DA, Sosenko JM. Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes. Pediatr Diabetes. 2024; 2024:8343868.
-
Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. 2024 Jun 01; 47(6):1048-1055.
-
Callebaut A, Guyer P, Baker RL, Gallegos JB, Hohenstein AC, Gottlieb PA, Mathieu C, Overbergh L, Haskins K, James EA. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. 2024 May 01; 73(5):743-750.
-
Rasouli N, Younes N, Ghosh A, Albu J, Cohen RM, DeFronzo RA, Diaz E, Sayyed Kassem L, Luchsinger JA, McGill JB, Sivitz WI, Tamborlane WV, Utzschneider KM, Kahn SE. Longitudinal Effects of Glucose-Lowering Medications on ?-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care. 2024 Apr 01; 47(4):580-588.
-
Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol. 2023 12; 11(12):915-925.
-
Hernandez TL, Farabi SS, Fosdick BK, Hirsch N, Dunn EZ, Rolloff K, Corbett JP, Haugen E, Marden T, Higgins J, Friedman JE, Barbour LA. Randomization to a Provided Higher-Complex-Carbohydrate Versus Conventional Diet in Gestational Diabetes Mellitus Results in Similar Newborn Adiposity. Diabetes Care. 2023 11 01; 46(11):1931-1940.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|